Abstract
Diabetic kidney disease (DKD) is a critical microvascular complication of diabetes and a primary driver of chronic kidney disease (CKD) globally. While renin-angiotensin-aldosterone system inhibitors (RASIs) are the standard of care, adjunctive therapies are often sought to improve outcomes. This systematic review and meta-analysis evaluates the efficacy and safety of combining Abelmoschus manihot (AM) capsules with RASI therapy. Analyzing 32 randomized controlled trials (RCTs) involving 2,881 patients, the study found that the combination therapy significantly improved renal biomarkers and reduced proteinuria compared to RASI monotherapy, maintaining a favorable safety profile.
Introduction
Diabetic kidney disease (DKD) remains the leading cause of end-stage kidney disease. Current clinical guidelines emphasize the use of ACE inhibitors (ACEIs) or Angiotensin-Receptor Blockers (ARBs) to manage blood pressure and reduce protein leakage. Despite these interventions, many patients experience persistent renal decline. In China, Abelmoschus manihot (AM) capsules, a proprietary Chinese patent medicine, are widely utilized as a complementary treatment. This paper provides a high-quality synthesis of clinical evidence to determine if the combination of AM and RASI offers superior therapeutic benefits over standard care.
Methods
The researchers conducted a systematic search across major English and Chinese databases, including PubMed, Cochrane Library, Embase, CNKI, and SinoMed, for RCTs published through March 2023. The inclusion criteria focused on studies comparing AM capsules plus RASI against RASI alone in DKD patients. Two independent investigators performed data extraction and assessed study quality using the Cochrane risk of bias tool. Meta-analysis was conducted using RevMan 5.4, employing random-effects models to account for expected study heterogeneity.
Results
The meta-analysis included 32 RCTs with a total of 2,881 patients (1,442 in the treatment group; 1,439 in the control group). The results demonstrated significant clinical improvements in the combination therapy group across several key metrics:
- Proteinuria Reduction: The AM + RASI group showed a significantly greater reduction in 24-hour urine total protein (24h-UTP) by an average of 442.05 mg (p < 0.00001) and urinary albumin excretion rate (UAER) by 30.53 μg/min (p < 0.00001).
- Renal Function Preservation: Serum creatinine (Scr) levels decreased by 6.80 μmol/L (p < 0.0001), and blood urea nitrogen (BUN) decreased by 0.59 mmol/L (p = 0.01), indicating improved filtration.
- Subgroup Insights: The combination of AM and ARB appeared more effective in reducing UAER than the AM and ACEI combination. Furthermore, patients with higher baseline protein leakage (>2g/24h) or elevated creatinine levels saw more pronounced benefits from the addition of AM.
Safety Profile
A critical finding of this review is the safety of the integrated approach. The analysis of adverse reactions (such as gastrointestinal discomfort or dizziness) showed no statistically significant difference between the combination group and the control group (OR = 1.06; 95% CI: 0.66, 1.69; p = 0.82). This suggests that AM capsules do not introduce additional toxicity when used alongside standard Western pharmacological treatments.
Discussion and Limitations
The study suggests that AM may work synergistically with RASIs by reducing inflammation and inhibiting renal fibrosis. However, the authors note several limitations that require cautious interpretation:
- High Heterogeneity: Significant variability ($I^2 > 90\%$) was observed, likely due to differences in drug dosages, patient demographics, and disease stages.
- Geographic Bias: Most trials were conducted in China and published in Chinese, which may affect the generalizability of the findings to other populations.
- Study Duration: Most trials were relatively short (8–24 weeks), leaving the long-term efficacy and safety of AM in chronic DKD management unclear.
- Methodological Quality: Some studies lacked detailed reporting on randomization and blinding, introducing potential bias.
Conclusion
Combining Abelmoschus manihot capsules with RASI therapy appears to be a superior strategy for managing DKD compared to RASI monotherapy, particularly in reducing proteinuria and stabilizing renal function. While the safety profile is encouraging, the high heterogeneity of current data underscores the need for large-scale, multi-center, double-blind RCTs with longer follow-up periods to solidify these findings in international clinical practice.
Summary updated